Pre-made Clenoliximab benchmark antibody (Whole mAb, anti-CD4 therapeutic antibody, Anti-IMD79/OKT4D Antibody) for drug discovery and mechanism of action (MOA) research

Anti-CD4 therapeutic antibody (Pre-made Clenoliximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and human.[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-782-1mg	1mg	3090
GMP-Bios-INN-782-10mg	10mg	Inquiry
GMP-Bios-INN-782-100mg	100mg	Inquiry
GMP-Bios-INN-782-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Clenoliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
INN Name	Clenoliximab
Target	CD4
Format	Whole mAb
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG4 - lambda
VD LC	IgG4 - lambda
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Biogen, Inc. (Cambridge MA USA) / GlaxoSmithKline (Brentford UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0